Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series.
| Autor: | Mukit FA; Ophthalmology, Hamilton Eye Institute, Memphis, USA., Manley A; Ophthalmology, The University of Tennessee Health Science Center, Memphis, USA., Patel AB; Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA., Hashemi M; Ophthalmology, The University of Tennessee Health Science Center, Memphis, USA., Laplant JF; Ophthalmic Plastic and Reconstructive Surgery, Medical College of Wisconsin, Milwaukee, USA., Fleming JC; Oculofacial Plastic and Reconstructive Surgery, Hamilton Eye Institute, Memphis, USA., Fowler BT; Oculofacial Plastic and Reconstructive Surgery, Hamilton Eye Institute, Memphis, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Apr 19; Vol. 16 (4), pp. e58585. Date of Electronic Publication: 2024 Apr 19 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.58585 |
| Abstrakt: | As the use of teprotumumab for thyroid eye disease (TED) becomes more prolific, there remains a scarcity of literature regarding the associated side effects and adverse events of teprotumumab use. The authors present a single-center retrospective, observational case review of TED patients who received at least a single dose of teprotumumab infusion at the oculofacial plastic surgery service between February 2020 and July 2023. The most predominant recollected side effects were fatigue, brittle nails, dry eye symptoms, hair loss, muscle spasms, and dry mouth. Significant adverse events were limited to two cases of a blood clot and a single case of pulmonary embolism. This is the first retrospective study of patient-reported side effects and adverse events experienced by a cohort of teprotumumab users. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Mukit et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|